

**For Release**

**Contact: Laura Feragen  
215-793-4666, Ext. 106  
lferagen@startoplin.com**

**CAPSALUS CORP. RECEIVES SPECULATIVE BUY RATING  
FROM INDEPENDENT ADVISORY FIRM**

**ATLANTA – March 9, 2011** – Capsalus Corp. (OTCBB: WELL), a company operating in the health and wellness space, has received a Speculative Buy recommendation from Opus Group Financial, an independent, financial advisory firm. Based on its analysis of Capsalus’ performance over its first 15 months (it was renamed from Mach One in Sept. 2010), Opus expects the company to record a profit as early as the second quarter of 2011, followed by rapid cash flow generation and margin enhancement.

The report attributes [Capsalus’ profitability potential \(http://www.capsalus.com/company/investment-strategy\)](http://www.capsalus.com/company/investment-strategy) to two key factors: Investments in promising development stage enterprises offering innovative products and services in fast-growing segments of the wellness sector, and low operating cost structure. According to Opus, with a current share price of \$0.04 and an M-Cap of \$13.53 million, Capsalus is undervalued in relation to the market and its peers. The company’s risk reward ratio advocates the purchase of its stock, despite the possibility of dilution. Any concerns over balance sheet weakness will be mitigated by the prospect of relatively quick returns from new investments and that a significant portion of Capsalus’ existing debt will be converted into equity, as indicated by Opus research.

Regarding stock price, Opus Analyst Robert Sassoon states, “Our DCF-based sum-of-the-parts valuation, adjusted for possible future stock dilution, suggests a fair value price range for Capsalus stock at between \$0.64 and \$0.95. In spite of the threat of significant stock dilution, we believe that the prospect of recording its first profit during 2011 will represent a major catalyst for a stock price re-rating. We rate the company a Speculative Buy, acknowledging that there are risks to our projections at this early stage of the company’s operating cycle.”

Overall, the long-term outlook for Capsalus is positive. View Opus' full [Capsalus Outlook report](http://www.capsalus.com/sites/default/files/uploads/Capsalus_Corp_Initiation_Research_Report.pdf)([http://www.capsalus.com/sites/default/files/uploads/Capsalus\\_Corp\\_Initiation\\_Research\\_Report.pdf](http://www.capsalus.com/sites/default/files/uploads/Capsalus_Corp_Initiation_Research_Report.pdf)).

# # #

[Capsalus Corp. \(www.capsalus.com\)](http://www.capsalus.com), based in Atlanta, is a public company that partners with and acquires visionary enterprises producing progressive, broad-based solutions in the health and wellness space for better physical, nutritional and emotional health worldwide. Capsalus, which derives its name from “Salus,” the Roman goddess of health and prosperity, provides companies in varying stages of development with the operating infrastructure, strategic pathways and financial support to get them to the mass market quickly and efficiently. Its current portfolio includes companies across the consumer products, media and technology, biotechnology and healthcare industry spectrum, including Wish Upon a Hero, an online community pioneering a new model of philanthropy by connecting people in need with people who can help; Guava Healthcare, specializing in providing customized in-home, non-medical and medical staffing and services to clients across the age spectrum; White Hat Brands, an emerging player in the branded functional food and beverage market; and PanTheryx, creating and selling biologics, pharmaceuticals and medical products to the expanding healthcare professional market in India. Capsalus™ is a trademark of Capsalus Corp.

***Forward-looking Statements***

*This news release may contain “Forward-looking Statements” within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements in this news release, other than statements of historical fact, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this news release.*